PE20060163A1 - Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas - Google Patents

Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas

Info

Publication number
PE20060163A1
PE20060163A1 PE2005000366A PE2005000366A PE20060163A1 PE 20060163 A1 PE20060163 A1 PE 20060163A1 PE 2005000366 A PE2005000366 A PE 2005000366A PE 2005000366 A PE2005000366 A PE 2005000366A PE 20060163 A1 PE20060163 A1 PE 20060163A1
Authority
PE
Peru
Prior art keywords
alkyl
independently
modulators
heterocyclic
compounds
Prior art date
Application number
PE2005000366A
Other languages
English (en)
Inventor
Paige Erin Mahaney
Stephen Todd Cohn
An Thien Vu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060163A1 publication Critical patent/PE20060163A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE FENILPROPANOL DE FORMULA (I), EN DONDE LA LINEA PUNTEADA ES UN DOBLE ENLACE OPCIONAL ENTRE U Y V O ENTRE V Y W; U ES INDEPENDIENTEMENTE O, S, SO(1-2), C=O, N, NR3 O C(R8)2; W ES CH, CH2, O C=O; SI W ES CH2, U NO ES C(R8)2; V ES C(R8), C(R8)2, O, O N(R8); R1 ES ALQUILO, HALOGENO, ENTRE OTROS; R2 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS CON R1; R3 ES H O ALQUILO(C1-C4), ENTRE OTROS; R4, ES INDEPENDIENTEMENTE H, ALQUILO(C1-C4), ENTRE OTROS; O AMBOS R4, JUNTO AL N, A TRAVES DEL CUAL SE FORMA UN ENLACE, FORMAN UN ANILLO, EN DONDE UN CARBONO PUEDE REEMPLAZARSE CON N, O, S O SO2 Y PUEDEN ESTAR SUSTITUIDOS POR ALQUILO(C1-C4),F O CF3; R5; R6 Y R7 SON INDEPENDIENTEMENTE H O ALQUILO(C1-C4), O R7 Y R4 JUNTO CON EL N AL QUE SE UNE R4 FORMAN UN ANILLO(C3-C6); R8 ES H, ALQUILO(C1-C4), HETEROARILO(C3-C6)O O ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-(2,3-DIHIDRO-4H-1,4-BENZOXAZIN-4-IL)-3-(METILAMINO)-1-FENILPROPAN-2-OL, 1-(6-CLORO-2,6-DIHIDRO-4H-1,4-BENZOXAZIN-4-IL)-1-(3,5-DIFLUOROFENIL)-3-(METILAMINO)PROPAN-2-OL.TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON UTILES EN LA PREVENCION Y TRATAMIENTO DE AFECCIONES QUE MEJORAN CON LA RECAPTACION DE MONOAMINAS COMO LOS SINTOMAS VASOMOTORES (SVM), DISFUNCION SEXUAL, TRANSTORNOS GENITOURINARIOS, GASTROINTESTINALES, DEL SISTEMA NERVIOSO CENTRAL, ENTRE OTRAS
PE2005000366A 2004-03-30 2005-03-30 Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas PE20060163A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55783104P 2004-03-30 2004-03-30
US56986104P 2004-05-11 2004-05-11
US11/091,291 US7414052B2 (en) 2004-03-30 2005-03-28 Phenylaminopropanol derivatives and methods of their use

Publications (1)

Publication Number Publication Date
PE20060163A1 true PE20060163A1 (es) 2006-04-17

Family

ID=34964470

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000366A PE20060163A1 (es) 2004-03-30 2005-03-30 Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas

Country Status (13)

Country Link
US (2) US7414052B2 (es)
EP (1) EP1730127B1 (es)
JP (1) JP2007531750A (es)
AR (1) AR048447A1 (es)
AT (1) ATE399158T1 (es)
AU (1) AU2005230899A1 (es)
BR (1) BRPI0509513A (es)
CA (1) CA2560966A1 (es)
DE (1) DE602005007718D1 (es)
PA (1) PA8628101A1 (es)
PE (1) PE20060163A1 (es)
TW (1) TW200538460A (es)
WO (1) WO2005097761A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
AU2005250116B2 (en) * 2004-06-01 2011-01-20 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
AR056544A1 (es) * 2005-09-29 2007-10-10 Wyeth Corp Derivados fenilaminopropanol y metodos de uso de los mismos
TW200817382A (en) * 2006-08-24 2008-04-16 Wyeth Corp Process for preparing indolinone phenylaminopropanol derivatives
WO2008042362A1 (en) * 2006-10-04 2008-04-10 Wyeth Arylamino-arylpropanolamine derivatives and methods of their use
CL2007003591A1 (es) * 2006-12-12 2008-02-29 Wyeth Corp Compuestos derivados de sulfonamida ciclicos, inhibidores de retoma de monoamina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de disfuncion sexual, trastorno gastrointestinal, trastorno genitourinari
US20090042874A1 (en) * 2007-05-30 2009-02-12 Wyeth Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans
EP2440202A1 (en) * 2009-06-10 2012-04-18 Abbott GmbH & Co. KG Use of substituted oxindole derivatives for the treatment and prophylaxis of pain
JP6078004B2 (ja) * 2011-01-20 2017-02-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ミネラルコルチコイド受容体拮抗薬

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454554A (en) 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
US4123543A (en) 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
CS175831B1 (es) 1974-12-17 1977-05-31
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
PH18686A (en) 1981-05-26 1985-08-29 Merck & Co Inc 1-(3 halo-2-pyridinyl) piperazine
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
EP0135905A3 (de) 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane
ZA864772B (en) 1985-07-02 1987-02-25 Merrell Dow Pharma Novel chemical compounds
CA1327795C (en) 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
ES2067937T3 (es) 1990-06-01 1995-04-01 Merrell Dow Pharma (+)-alfa-(2,3-dimetoxifenil)-1-(2-(4-fluorofenil)etil)-4-piperidinametanol.
US5648511A (en) 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502047A (en) 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
WO1996005818A1 (en) 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU5857296A (en) 1995-05-17 1996-11-29 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
UA48219C2 (uk) 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
WO1998014208A1 (en) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Reactive ligands and covalent ligand-protein complexes
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
KR20010015918A (ko) 1998-03-02 2001-02-26 피터 지. 스트링거 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
TW528754B (en) 1998-04-29 2003-04-21 Wyeth Corp Indolyl derivatibes as serotonergic agents
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
CZ20013607A3 (cs) 1999-04-06 2002-06-12 Sepracor Inc. Farmaceutický prostředek
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
PT1459751E (pt) 1999-07-01 2005-11-30 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para tratar as enxaquecas
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
WO2001072708A2 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
GB2362826A (en) 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1318988A2 (en) 2000-09-11 2003-06-18 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
JP4220243B2 (ja) 2001-02-12 2009-02-04 ワイス Ｏ−デスメチル−ベンラファキシンの新規コハク酸塩
CA2442410A1 (en) 2001-03-29 2002-10-10 Owen Brendan Wallace Duloxetine for treatment of hot flashes
EP1266659A1 (en) 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
WO2003010169A1 (en) 2001-07-25 2003-02-06 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene
US6794385B2 (en) * 2001-08-08 2004-09-21 Pharmacia & Upjohn, S.P.A. Benzoxazine derivatives useful as integrin receptor antagonists
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US20040259850A1 (en) 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
TW200402289A (en) 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
AU2003261185A1 (en) 2002-08-14 2004-03-03 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
US20040152710A1 (en) 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US20050165082A1 (en) 2003-12-16 2005-07-28 Wyeth Methods of treating vasomotor symptoms
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use

Also Published As

Publication number Publication date
JP2007531750A (ja) 2007-11-08
BRPI0509513A (pt) 2007-09-11
AU2005230899A1 (en) 2005-10-20
US20080255102A1 (en) 2008-10-16
CA2560966A1 (en) 2005-10-20
WO2005097761A1 (en) 2005-10-20
EP1730127B1 (en) 2008-06-25
EP1730127A1 (en) 2006-12-13
DE602005007718D1 (de) 2008-08-07
PA8628101A1 (es) 2005-11-25
US7638512B2 (en) 2009-12-29
US20050222142A1 (en) 2005-10-06
ATE399158T1 (de) 2008-07-15
AR048447A1 (es) 2006-04-26
US7414052B2 (en) 2008-08-19
TW200538460A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
PE20060163A1 (es) Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PE20010574A1 (es) Derivados de indol como ligandos del receptor 5-ht2
PE20050951A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
CO5630029A2 (es) Derivados de indol e indolina sustituidos
PE20060288A1 (es) Derivados de fenilaminopropanol
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
AR048523A1 (es) Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
PE20200608A1 (es) Nuevos derivados de azaquinolina
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
AR040349A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
AR056445A1 (es) Derivados arilicos y heteroarilicos de 6 miembros para tratar virus
PE20091524A1 (es) Derivados de 2-aminopirimidina
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR050274A1 (es) Derivados triciclicos del indeno-pirrol como moduladores de la serotonina
PE20050726A1 (es) Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal